You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03
|
|---|---|
| Published in |
Clinical and Translational Oncology, January 2023
|
| DOI | 10.1007/s12094-023-03085-w |
| Pubmed ID | |
| Authors |
Jesus Garcia-Donas, Alicia Hurtado, Laia Garrigos, Ana Santaballa, Andres Redondo, Laura Vidal, Nuria Lainez, Eva Guerra, Victor Rodriguez, Juan Cueva, Isabel Bover, Isabel Palacio, Maria Jesus Rubio, Mario Prieto, Jose Antonio Lopez-Guerrero, Juan Francisco Rodriguez-Moreno, Zaida Garcia-Casado, Elena Garcia-Martinez, Alvaro Taus, Ignacio Pérez de Castro, Paloma Navarro, Enrique Grande |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 9 | 69% |
| Unknown | 4 | 31% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 11 | 85% |
| Scientists | 1 | 8% |
| Practitioners (doctors, other healthcare professionals) | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 5 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 5 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 2 | 40% |
| Unspecified | 1 | 20% |
| Unknown | 2 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Unspecified | 1 | 20% |
| Biochemistry, Genetics and Molecular Biology | 1 | 20% |
| Sports and Recreations | 1 | 20% |
| Unknown | 2 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 June 2023.
All research outputs
#2,461,216
of 25,392,582 outputs
Outputs from Clinical and Translational Oncology
#77
of 1,464 outputs
Outputs of similar age
#50,726
of 472,532 outputs
Outputs of similar age from Clinical and Translational Oncology
#1
of 42 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,464 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 472,532 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.